After completing this module, participants should be better able to understand:
- Although good glycaemic control in diabetes remains the optimal way to reduce microvascular complications, cardiovascular risk reduction is a priority in the management of type 2 diabetes
- Lifestyle intervention may not provide cardiovascular (CV) benefit in those with diabetes, although, as it improves overall wellbeing, it should still be advocated
- Good blood pressure control, however achieved, is essential
- People with diabetes should receive a statin unless there is a compelling reason not to
- If cholesterol targets are not achieved on statin alone, or a patient is intolerant, ezetimibe may provide additional benefit in those with diabetes and previous CV event
- There is no role in primary prevention for antithrombotics, although aspirin and/or clopidogrel should be used in secondary prevention
- Newer biological agents may have a role in the very high risk, however, the cost-effectiveness of such strategies has not been evaluated
W David Strain, Clinical Senior Lecturer and Honorary Consultant, University of Exeter Medical School, Institute of Biomedical and Clinical Science, Department of Diabetes and Vascular Research, Royal Devon & Exeter Hospital
With thanks to Dr Sam Pearson, Specialist Registrar in Diabetes and Endocrinology, St James’s University Hospital, Leeds, for assistance on the self-assessment aspect of the programme.
0.5 CPD/CME credit, 0.5 hours
BJC Learning has assigned half an hour of CPD/CME credit to this module
You need to login to take this module
You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.